Vir Biotechnology announced that the FDA has cleared its investigational new drug, or IND, application and granted Fast Track designation for the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection. Tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, are currently being evaluated in the company’s Phase 2 SOLSTICE hepatitis delta clinical trial, with complete 24-week treatment data on track to be reported in the fourth quarter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Biotech Alert: Searches spiking for these stocks today
- Vir Biotechnology price target raised to $15 from $12 at Morgan Stanley
- Vir Biotechnology price target raised to $13 from $12 at JPMorgan
- Vir Biotechnology combo shows ‘unprecedented’ response, says H.C. Wainwright
- Vir Biotechnology Anticipates Promising Hepatitis Trial Results